Fortress Biotech ($FBIO) is currently trading at a market cap below the value of its cash and shares in other publicly traded companies it owns. The company's preferred shares have a cumulative perpetual dividend that may be reactivated soon. One of their subsidiaries is approaching a PDUFA on September 30, which could lead to a PRV worth more than the current valuation of the company. Additionally, Fortress has funded and created multiple companies, such as Cyprium and Journey, and still holds significant stakes in them. The company's influence extends beyond being a passive shareholder, as they have the ability to steer strategy when needed.

FBIO stock price is 3.81. FBIO 52 Week low is None. FBIO 52 Week high is None. FBIO 200 day moving average is 1.9. It is currently trading above 200 day moving average. FBIO 50 day moving average is 2.24 which is below(bullish) the current price. RSI (relative strength index) of FBIO is 79.914 which is above (bullish) 70. Chaikin money flow (20 day) of FBIO is 0.235 which is above (bullish) 0.